Lingotto Investment Management LLP Raises Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Lingotto Investment Management LLP increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 1.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,156,918 shares of the company’s stock after purchasing an additional 302,975 shares during the quarter. Teva Pharmaceutical Industries comprises about 10.0% of Lingotto Investment Management LLP’s portfolio, making the stock its 3rd biggest holding. Lingotto Investment Management LLP owned 2.45% of Teva Pharmaceutical Industries worth $471,910,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TEVA. US Bancorp DE raised its position in shares of Teva Pharmaceutical Industries by 6.5% during the 1st quarter. US Bancorp DE now owns 10,812 shares of the company’s stock worth $166,000 after buying an additional 656 shares in the last quarter. MAI Capital Management increased its stake in shares of Teva Pharmaceutical Industries by 26.8% during the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after acquiring an additional 697 shares during the period. Wedbush Securities Inc. raised its holdings in Teva Pharmaceutical Industries by 3.3% during the second quarter. Wedbush Securities Inc. now owns 21,995 shares of the company’s stock worth $369,000 after purchasing an additional 700 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Teva Pharmaceutical Industries by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company’s stock worth $92,000 after purchasing an additional 715 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in Teva Pharmaceutical Industries by 1.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,445 shares of the company’s stock worth $929,000 after purchasing an additional 762 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $25.86.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $28.39 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The firm has a market cap of $32.56 billion, a PE ratio of 47.32, a P/E/G ratio of 1.50 and a beta of 0.67. The business has a fifty day simple moving average of $22.28 and a 200-day simple moving average of $19.09. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $28.46.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the business’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the sale, the director owned 495,000 shares in the company, valued at approximately $11,934,450. The trade was a 28.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.